Interestingly, PD-1 blockade reverses glucose restriction in TILs (tumor killer cells), enhancing CD8+ T cells glucose influx and glycolysis via mTOR signaling, which allows IFN-γ production, improving their effector anti-tumor function [8]. The gene discussed is MTOR; the disease is neoplasm.